Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener Medizinische Wochenschrift
Erschienen in:

12.06.2017 | übersicht

Orale Antikoagulation mit Vitamin K-Antagonisten – ein Update

verfasst von: Priv.-Doz. Dr. med. habil. Christoph Sucker, Jens Litmathe

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 5-6/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Vitamin K-Antagonisten (VKA) werden zur Prophylaxe und Therapie thrombotischer bzw. thromboembolischer Ereignisse eingesetzt; die wichtigsten Indikationen sind die Antikoagulation bei tiefer Venenthrombose und Lungenembolie, die Antikoagulation bei Patienten mit Vorhofflimmern sowie die Antikoagulation bei Patienten mit mechanischem Herzklappenersatz und somit gelebter Alltag vor dem Hintergrund potentieller kardio-neurologischer Ereignisse. Mit der vorliegenden Arbeit soll ein Überblick über die Antikoagulation mit VKA gegeben werden; hierbei wird auf Wirkungsmechanismen, Indikationen und Effektivität, Durchführung der Antikoagulation, Nebenwirkungen und Monitoring der Behandlung eingegangen.
Vorheriger Artikel LDL-Cholesterin und kardiovaskuläre Ereignisse: je niedriger desto besser?
Nächster Artikel Edoxaban zur Schlaganfallprophylaxe bei Patienten mit nicht-valvulärem Vorhofflimmern und zur Behandlung venöser Thromboembolien: ein interdisziplinäres Positionspapier
Literatur
1.
Amin A, Marrs JC. Direct oral anticoagulants for the management of Thromboembolic disorders: the importance of adherence and persistence in achieving beneficial outcomes. Clin Appl Thromb Hemost. 2016;22:605–16.CrossRefPubMed
2.
Ansell J. Point-of-care patient self-monitoring of oral vitamin K antagonist therapy. J Thromb Thrombolysis. 2013;35:339–41.CrossRefPubMed
3.
Ansell J, Jacobson A, Levy J, International Self-Monitoring Association for Oral Anticoagulation, et al. Guidelines for implementation of patient self-testing and patient self-management of oral anticoagulation. International consensus guidelines prepared by International Self-Monitoring Association for Oral Anticoagulation. Int J Cardiol. 2005;9:37–45.CrossRef
4.
Barcellona D, Fenu L, Cornacchini S, Marongiu F. Telemedicine can improve the quality of oral anticoagulation using portable devices and self-testing at home. J Telemed Telecare. 2013;19:298–301.CrossRefPubMed
5.
Becattini C, Agnelli G, Schenone A, et al. WARFASA Investigators. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012;366:1959–67.CrossRefPubMed
6.
Benmira S, Banda ZK, Bhattacharya V. Old versus new anticoagulants: focus on pharmacology. Recent Pat Cardiovasc Drug Discov. 2010;5:120–37.CrossRefPubMed
7.
Bernardo A, Völler H. Arbeitsgemeinschaft Selbstkontrolle der Antikoagulation. Guidelines for „coagulation self-management“. Dtsch Med Wochenschr. 2001;126:346–51.CrossRefPubMed
8.
Berthold HK. New oral anticoagulants for the prevention of stroke. Open questions in geriatric patients. Z Gerontol Geriatr. 2012;45:498–504.CrossRefPubMed
9.
10.
11.
Booth SL, Charnley JM, Sadowski JA, Saltzman E, Bovill EG, Cushman M. Dietary vitamin K1 and stability of oral anticoagulation: proposal of a diet with constant vitamin K1 content. Thromb Haemost. 1997;77:504–9.PubMed
12.
Braun S, Völler H, Soppa C, Taborski U. Update of guidelines for patient self-management of oral anticoagulation. Dtsch Med Wochenschr. 2009;134:695–700.CrossRefPubMed
13.
Brighton TA, Eikelboom JW, Mann K, et al. ASPIRE Investigators. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med. 2012;367:1979–87.CrossRefPubMed
14.
Butt HR, Allen EU, Bollman JL. A preparation from spoiled sweet clover C3, 3 methylene-bis- (4 hydroxy-coumarin) which prolongs coagulation and prothrombin time of 120 blood: preliminary report of experiments and clinical studies. Proceedings of the statt meetings. Mayo Clin. 1941;16:388–95.
15.
Campbell HA, Link KP. Studies on the hemorrhagic sweet clover disease. IV. The isolation and crystallization of the hemorrhagic agent. J Biol Chem. 1941;138:21–33.
16.
Daly AK. Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms. Arch Toxicol. 2013;87:407–20.CrossRefPubMed
17.
Diener HC, Executive Steering Committee of the SPORTIFF III and V Investigators, et al. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies. Cerebrovasc Dis. 2006;21:279–93.CrossRefPubMed
18.
Eikelboom JW, Connolly SJ, Brueckmann M, RE-ALIGN Investigators, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206–14.CrossRefPubMed
19.
Freedman MD, Olatidoye AG. Clinically significant drug interactions with the oral anticoagulants. Drug Saf. 1994;10:381–94.CrossRefPubMed
20.
Go AS. Efficacy of anticoagulation for stroke prevention and risk stratification in atrial fibrillation: translating trials into clinical practice. Am J Manag Care. 2004;10(Suppl.3):58–65.
21.
van Gorp RH, Schurgers LJ. New Insights into the Pros and Cons of the Clinical Use of Vitamin K Antagonists (VKAs) Versus Direct Oral Anticoagulants (DOACs). Nutrients. 2015;7:9538–57.CrossRefPubMedPubMedCentral
22.
Hana A, Berthold C, Gunness VR, Hana A, Dooms G, Standhardt H, Koy J, Matgé G, Boecher-Schwarz H, Hertel F. NOAC and intracerebral bleeding – presentation of four cases and review of the literature. Bull Soc Sci Med Grand Duche Luxemb. 2014;1:57–66.
23.
Hanslik T, Prinseau J. The use of vitamin K in patients on anticoagulant therapy: a practical guide. Am J Cardiovasc Drugs. 2004;4:43–55.CrossRefPubMed
24.
Harder S, Thürmann P. Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet. 1996;30:416–44.CrossRefPubMed
25.
Horstkotte D, Piper C. Improvement of oral anticoagulation therapy by INR self-management. J Heart Valve Dis. 2004;13:335–8.PubMed
26.
Hu Z, Yang X, Ho PC, et al. Herb-drug interactions: a literature review. Drugs. 2005;65:1239–82.CrossRefPubMed
27.
Jamal SA, Browner WS, Bauer DC, Cummings SR. Warfarin use and risk for osteoporosis in elderly women. Study of Osteoporotic Fractures Research Group. Ann Intern Med. 1998;128:829–32.CrossRefPubMed
28.
Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:454–545.CrossRef
29.
Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic Therapy for VTE Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(Suppl 2):419–94.CrossRef
30.
Krabbe B, Bauersachs RM. Bridging in patients with long-term oral anticoagulation – new recommendations. Dtsch Med Wochenschr. 2016;141:157–60.CrossRefPubMed
31.
32.
Le Heuzey JY, Ammentorp B, Darius H, De Caterina R, Schilling RJ, Schmitt J, Zamorano JL, Kirchhof P. Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry. Thromb Haemost. 2014;111:833–41.CrossRefPubMed
33.
Linkins LA. Bleeding risks associated with vitamin K antagonists. Blood Rev. 2013;27:111–8.CrossRefPubMed
34.
Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011;57:173–80.CrossRefPubMed
35.
Mair H, Sachweh J, Sodian R, et al. Long-term self-management of anticoagulation therapy after mechanical heart valve replacement in outside trial conditions. Interact Cardiovasc Thorac Surg. 2012;14:253–7.CrossRefPubMed
36.
Mentré F, Pousset F, Comets E, et al. Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients. Clin Pharm Therap. 1998;63:64–78.CrossRefPubMed
37.
Neef M, Kerekes Z, Fischer HP, Sauerbruch T, Spengler U. Acenocoumarol is not a safe alternative for anticoagulation in phenprocoumon-induced hepatic failure. Report of two cases. Digestion. 2003;67:100–4.CrossRefPubMed
38.
Oldenburg J, Bevans CG, Fregin A, Geisen C, Müller-Reible C, Watzka M. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles. Thromb Haemost. 2007;98:570–8.CrossRefPubMed
39.
Olthof E, de Vries TW. Breast feeding and oral anticoagulants. Tijdschr Kindergeneeskd. 1993;61:175–7.PubMed
40.
Pilon D, Castilloux AM, Dorais M, LeLorier J. Oral anticoagulants and the risk of osteoporosis fractures among elderly. Pharmacoepidemiol Drug Saf. 2004;13:289–94.CrossRefPubMed
41.
Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1‑year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093–100.CrossRefPubMed
42.
Quinn GR, Singer DE, Chang Y, et al. Effect of selective serotonin Reuptake inhibitors on bleeding risk in patients with atrial fibrillation taking warfarin. Am J Cardiol. 2014;114:583–6.CrossRefPubMedPubMedCentral
43.
Räber L, Piccolo R. CardioPulse: Different bleeding scores and which one should we use ? Eur Heart J. 2016;37:327–31.CrossRefPubMed
44.
Riley P, Maan A, Korr KS. Direct Oral Anticoagulants (DOAcs): current status among distinct patient subgroups. R I Med J. 2017;100:18–22.
45.
Roderick LM. The pathology of sweet clover disease in cattle. J Am Vet Med Assoc. 1929;74:314–5.
46.
Rodriguez-Castro KI, Simioni P, Burra P, Senzolo M. Anticoagulation for the treatment of thrombotic complications in patients with cirrhosis. Liver Int. 2012;32:1465–76.CrossRefPubMed
47.
Rohde LE, de Assis MC, Rabelo ER. Dietary vitamin K intake and anticoagulation in elderly patients. Curr Opin Clin Nutr Metab Care. 2007;10:1–5.PubMed
48.
Samsa GP, Matchar DB, Goldstein LB, et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med. 2000;160:967–73.CrossRefPubMed
49.
Sawicki PT. A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. Working Group for the Study of Patient Self-Management of Oral Anticoagulation. JAMA. 1999;281:145–50.CrossRefPubMed
50.
Schimanski CC, Burg J, Möhler M, et al. Phenprocoumon-induced liver disease ranges from mild acute hepatitis to (sub-)acute liver failure. J Hepatol. 2004;41:67–74.CrossRefPubMed
51.
Siguret V. Impact of pharmacogenetics on interindividual variability in the response to vitamin K antagonist therapy. Pathol Biol (Paris). 2007;55:295–8.CrossRef
52.
Sjögren V, Grzymala-Lubanski B, Renlund H, Friberg L, Lip GY, Svensson PJ, Själander A. Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula. Thromb Haemost. 2015;113:1370–7.CrossRefPubMed
53.
Taborski U, Wittstamm FJ, Bernardo A. Cost-effectiveness of self-managed anticoagulant therapy in Germany. Semin Thromb Hemost. 1999;25:103–7.CrossRefPubMed
54.
Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet. 2005;44:1227–46.CrossRefPubMed
55.
56.
Van de Werf F, Brueckmann M, Connolly SJ, et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J. 2012;163:931–7.CrossRefPubMed
57.
Vermeer C, Hamulyák K. Pathophysiology of vitamin K‑deficiency and oral anticoagulants. Thromb Haemost. 1991;66:153–9.PubMed
58.
Vermeer C, Schurgers LJ. A comprehensive review of vitamin K and vitamin K antagonists. Hematol Oncol Clin North Am. 2000;14:339–53.CrossRefPubMed
59.
Watzka M, Geisen C, Bevans CG, et al. Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment. J Thromb Haemost. 2011;9:109–18.CrossRefPubMed
60.
61.
Yurdakök M. Fetal and neonatal effects of anticoagulants used in pregnancy: a review. Turk J Pediatr. 2012;54:207–15.PubMed
Metadaten
Titel
Orale Antikoagulation mit Vitamin K-Antagonisten – ein Update
verfasst von
Priv.-Doz. Dr. med. habil. Christoph Sucker
Jens Litmathe
Publikationsdatum
12.06.2017
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 5-6/2018
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-017-0577-z

Weitere Artikel der Ausgabe 5-6/2018

LDL-Cholesterin und kardiovaskuläre Ereignisse: je niedriger desto besser?

  • übersicht

Rezension

  • rezension

Pulmonalembolie und direkte orale Antikoagulantien

  • Open Access
  • short communication

Successful re-ablation of a permanent junctional reciprocating tachycardia with cryoenergy

  • case report

Herzluxation und Torsion nach erweiterter Pneumonektomie

  • case report

Defi macht Schule

  • originalarbeit